Empowering People to be Ambassadors of their Own Health Since 1997.


We promise to be bold in creating change.
We challenge you to be bold in your unique journey to wellness.

By providing state-of-the-art information and services to address the knowledge gaps in Hepatitis C, we intend to change the course of this urgent public health crisis. We cannot do this without you. Get Involved. Become an advocate today! Apply NOW for the Hepatitis Leadership Corps Learn more >>

Caring Ambassadors is excited to announce the release of

Hep C Discussion Point™

Try this free powerful and interactive online tool for people living with hepatitis C !


Breaking News!

We are one step closer to eradicating this virus!

Today the US Food and Drug Administration (FDA) announced the approval of Gilead’s NS5A inhibitor Ledipasvir, a powerful new tool for treating hepatitis C (HCV). The combination of ledipasvir and sofosbuvir (Sovaldi™), Gilead’s nucleotide analog polymerase inhibitor that was approved late last year, has proven highly effective in curing HCV genotype 1. The approval of this new regimen, called Harvoni™ marks a significant step forward as it represents the first all-oral interferon-free treatment officially available to the millions of Americans living with HCV.

The combination regimen of ledipasvir and sofosbuvir was approved by the FDA as a once-daily fixed-dose treatment for chronic hepatitis C genotype 1 infection in adults. Approximately 75 percent of people infected with HCV in the United States have the genotype 1 strain of the virus. The new therapy is considered an advance not only because of the high cure rates that it has been able to achieve, but because of the simplicity of administration and the limited side effects, primarily fatigue and headache. Because this treatment has been approved as an interferon-free regimen, many Americans who previously failed treatment or were ineligible or unwilling to undergo treatment due to the harsh side effects of previous treatments will have the opportunity to be cured of their disease.

The focus must now shift to ensuring that all patients who are interested in this therapy have access to the current drug regimen. Caring Ambassadors encourages all parties- industry leaders and community advocates, patients and policymakers-to come to the table and work together to find solutions that will benefit everyone. We are now one step closer to eradicating the hepatitis C virus once and for all; we cannot let this opportunity go to waste.



Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)